"These presentations highlight new potential applications for our vascular disrupting agents, which are currently in clinical development for other indications," stated
Titles of the presentations by Mateon and/or its collaborators include the following:
Combining Vascular Disrupting Agents with Checkpoint Inhibitors to Improve Tumour Immunogenicity.
Targeting Tumor-Associated Hypoxia with Bioreductively Activatable Prodrug Conjugates of Small-Molecule Inhibitors of Tubulin Polymerization.
Cathepsin inhibition impairs M2 macrophage pro-tumor functions.
The small molecule Cathepsin L and K inhibitor KGP-94 impairs the Tumor-Associated Macrophage-mediated metastatic phenotype of osteosarcoma under hypoxia.
At Mateon, we believe that we can significantly improve cancer therapy by employing these two complementary approaches simultaneously. When utilized this way, VDAs obstruct existing blood vessels in the tumor leading to significant central tumor cell death while AAs prevent the formation of new tumor blood vessels.
Mateon is committed to leveraging our intellectual property and the product development expertise of our highly skilled management team to enable VTT to realize its true potential and to bring much-needed new therapies to cancer patients worldwide.
Safe Harbor Statement
Certain statements in this news release, including, but not limited to, those concerning the advancement of the company's preclinical programs and the results of clinical trials, the potential significance of this data and its relation to other clinical and preclinical studies
are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. They can be affected by inaccurate assumptions Mateon might make or by known or unknown risks and uncertainties, including, but not limited to: the uncertainties as to the future success of ongoing and planned clinical trials; the unproven safety and efficacy of products under development or that may be developed in the future; and the sufficiency of the Company's cash resources to conduct and complete future clinical and preclinical trials. Consequently, no forward-looking statement can be guaranteed, and actual results may vary materially. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in Mateon's reports to the
PCG Advisory Group Stephanie Prince, Managing Director email@example.com 646-762-4518 Media: JPA Health Communications Nic DiBellanic@jpa.com 617-945-5183
News Provided by Acquire Media